FDA grants accelerated approval of Perjeta for people with HER2-positive early stage
The U.S. Food and Drug Administration granted accelerated approval of a Perjeta- (pertuzumab) regimen for neoadjuvant treatment (use before surgery) in people with high-risk, HER2-positive early stage breast cancer.
Linear Mode
